Cyclopharm (ASX:CYC) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 11, 2026)


ASX:CYC Cyclopharm Ltd ASX:CYC
45 GF Score
Price A$0.53
GF Value A$0.83
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cyclopharm 5-Year Yield-on-Cost %?

Cyclopharm ASX:CYC +2.94% 45 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus rates ASX:CYC with a GF Score™ of 45/100 and a GF Value™ of A$0.83 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 69 Medical Distribution companies, Cyclopharm ranks worse than 1449273.91% on this metric.

Cyclopharm's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Cyclopharm's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, Cyclopharm's highest Yield on Cost was 1.38. The lowest was 0.32. And the median was 0.68.


ASX:CYC's 5-Year Yield-on-Cost % is not ranked *
in the Medical Distribution industry.
Industry Median: 3.25
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Cyclopharm  (ASX:CYC) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cyclopharm 5-Year Yield-on-Cost % Related Terms


ASX:CYC vs MCK, CAH, COR: 5-Year Yield-on-Cost % Comparison

For the Medical Distribution subindustry, Cyclopharm's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclopharm 5-Year Yield-on-Cost % vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Cyclopharm's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cyclopharm's 5-Year Yield-on-Cost % falls into.


ASX:CYC
45GF Score
Cyclopharm Ltd ASX:CYC
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclopharm 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cyclopharm is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Cyclopharm (ASX:CYC) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cyclopharm and its competitors. Over the past decade, Cyclopharm's 5-Year Yield-on-Cost % has ranged from 0.32 to 1.38. According to the industry distribution chart, Cyclopharm ranks #999999 out of 69 companies in the Medical Distribution industry.
Is Cyclopharm's 5-Year Yield-on-Cost % too high?
Cyclopharm's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 1.38. Based on the distribution chart, Cyclopharm ranks #999999 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's 5-Year Yield-on-Cost % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #999999 out of 69 companies for 5-Year Yield-on-Cost %. This places Cyclopharm in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.25. Historically, Cyclopharm's own 5-Year Yield-on-Cost % has ranged from 0.32 to 1.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.25, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.83, compared to a current price of A$0.53 — trading 36.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Cyclopharm's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.53 is trading 36.7% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: A$0.83 vs. price of A$0.53 (36.7% below fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
45GF Score

Get the complete analysis for ASX:CYC

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.53
Price
A$0.83
GF Value